David Badawi Sells 5,980 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 5,980 shares of Sight Sciences stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total value of $13,754.00. Following the completion of the sale, the chief technology officer now directly owns 1,836,704 shares in the company, valued at $4,224,419.20. This represents a 0.32 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

David Badawi also recently made the following trade(s):

• On Friday, January 17th, David Badawi sold 5,423 shares of Sight Sciences stock. The stock was sold at an average price of $2.78, for a total value of $15,075.94.
• On Wednesday, January 8th, David Badawi sold 3,829 shares of Sight Sciences stock. The shares were sold at an average price of $3.26, for a total value of $12,482.54.
• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The stock was sold at an average price of $3.52, for a total transaction of $10,950.72.

Sight Sciences Price Performance

Shares of SGHT stock traded down $0.02 during trading on Thursday, hitting $2.23. The company had a trading volume of 358,040 shares, compared to its average volume of 208,670. The firm has a market capitalization of $114.47 million, a P/E ratio of -2.19 and a beta of 2.52. Sight Sciences, Inc. has a one year low of $2.05 and a one year high of $8.45. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. The stock’s 50-day moving average price is $2.68 and its 200 day moving average price is $3.89.

Sight Sciences (NASDAQ:SGHT) last released its earnings results on Wednesday, March 5th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). The company had revenue of $19.07 million for the quarter, compared to the consensus estimate of $18.98 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. During the same quarter in the previous year, the company posted ($0.22) earnings per share. Equities analysts expect that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on SGHT. Lake Street Capital reduced their target price on shares of Sight Sciences from $3.00 to $2.50 and set a “hold” rating for the company in a report on Thursday, March 6th. UBS Group reduced their price objective on shares of Sight Sciences from $5.50 to $5.00 and set a “buy” rating for the company in a research note on Monday, January 27th. Citigroup lowered their target price on Sight Sciences from $4.60 to $3.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Stifel Nicolaus reduced their price target on Sight Sciences from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Finally, Piper Sandler decreased their price objective on shares of Sight Sciences from $5.50 to $3.50 and set a “neutral” rating for the company in a research report on Thursday, March 6th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Sight Sciences presently has an average rating of “Hold” and a consensus price target of $3.83.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SGHT. ProShare Advisors LLC acquired a new stake in shares of Sight Sciences in the 4th quarter valued at $36,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Sight Sciences during the 4th quarter worth $40,000. Arkadios Wealth Advisors bought a new stake in shares of Sight Sciences during the 4th quarter worth $47,000. WealthTrust Asset Management LLC acquired a new stake in Sight Sciences in the fourth quarter valued at about $48,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Sight Sciences in the fourth quarter valued at about $50,000. 55.51% of the stock is owned by institutional investors.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.